Reducing circulating estrogen levels increases osteoclast activity and, therefore, bone loss. 9 Not only is the balance of osteoblasts and osteoclasts altered, but the microenvironment of the ...
The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback